AVROBIO falls after CEO leaves, co names interim chief
** Shares of gene therapy developer AVROBIO Inc AVRO.O
fall ~13% to 86 cents
** Co says CEO Geoff MacKay is leaving AVRO to join an
emerging early-stage company
** AVRO names Erik Ostrowski as interim CEO, who will also
continue as chief financial officer
** The board of directors has begun a search to identify a
permanent CEO - AVRO
** Stock up ~22% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Recent news on Tectonic Therapeutic
See all newsTectonic Therapeutic Inc reports results for the quarter ended June 30 - Earnings Summary
Tectonic Therapeutic Q2 net loss widens on higher costs
Tectonic Therapeutic Inc expected to post a loss of $1.35 a share - Earnings Preview
Brief: Tectonic Therapeutic Completes Enrollment In Tx45 Apex Phase 2 Clinical Trial In Ph-Hfpef Patients
Tectonic Therapeutic Q1 net loss widens on higher R&D costs